COMMUNIQUÉS West-GlobeNewswire

Erasca Announces $45 Million Oversubscribed Private Placement Financing
28/03/2024
Funding from new and existing investors extends anticipated cash runway into H2 2026 SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company [...]
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
28/03/2024
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 [...]
BioSyent Announces Grant of Restricted Share Units
27/03/2024
MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to [...]
By 2035, Canada could have the most enviable healthcare system in the world if obesity is recognized as a chronic disease, predicts Obesity Canada
27/03/2024
EDMONTON, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- Nearly 30,000 deaths from noncommunicable diseases in Canada in 2019, were due to high body mass index (BMI), most related to diabetes, cardiovascular disease, and [...]
Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group
27/03/2024
The network of physician-driven psychiatric practices continues to expand across the Southeastern United States to enhance patient care BATON ROUGE, La., March 27, 2024 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners , a [...]
American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results
27/03/2024
- Acquisition of 3 Rhode Island Radiation Therapy Cancer Centers progressing toward closing- - International Cancer Center equipment upgrade completed in Ecuador, Opening new Puebla, Mexico Center in Q2- - Lease [...]
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
27/03/2024
TORONTO and HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), is pleased to announce that, the Company completed a combined exercise and [...]
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
27/03/2024
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27/03/2024
MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
27/03/2024
Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with Medtronic, plc (NYSE: [...]
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
27/03/2024
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage [...]
Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results
27/03/2024
2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI ® -Burn Indication in the UK On Track [...]
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
27/03/2024
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program [...]
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
27/03/2024
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
27/03/2024
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the [...]
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
27/03/2024
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
Sharecare to report fourth quarter and full year fiscal 2023 financial results on Thursday, March 28
27/03/2024
ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced that it will report fourth quarter and full year [...]
Rakovina Therapeutics Announces Strategic Pivot to AI
27/03/2024
Company Leveraging Deep Docking AI Drug Discovery Platform VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical [...]
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27/03/2024
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions [...]

Pages